Menu
A recent drug industry-funded white paper drew a connection between 340B and increases in commercial insurance premiums, but provider advocates and attorneys criticized its methodology and findings.

Drug Industry-Funded White Paper Ties 340B to Rising Commercial Insurance Premiums; Provider Advocates Criticize Study

Bella Czajkowski, National Correspondent 340B Report Views
The 340B program is driving up employer-sponsored health insurance premiums, according to a drug industry-funded white paper. Provider advocates criticized [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Post Navigation

Chelsea Reddoch, Director of Product – 340B Recovery, R1

AbbVie, Sobi, Organon Exempt More States from 340B Contract Pharmacy Restrictions

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Site Footer Live